|
PSI CRO Korea |
[PSI CRO Korea] Regulatory Officer / Senior Regulatory O
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
05.04 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
07.21 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
08.29 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
08.28 |
|
|
ÀÌ¿ÀÇ÷οì ÁÖ½Äȸ»ç |
[ÀÌ¿ÀÇ÷οì] CRA ä¿ë(°ú/Â÷Àå)
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.04 |
|
|
ÀÌ¿ÀÇ÷οì ÁÖ½Äȸ»ç |
[ÀÌ¿ÀÇ÷οì] HW°³¹ß ´ã´çÀÚ Ã¤¿ë(´ë¸®±Þ)
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
04.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
07.17 |
|
|
À£¸¶Ä¿¹ÙÀÌ¿À |
À£¸¶Ä¿¹ÙÀÌ¿À ½Å±ÔÇ×¾ÏÁ¦ ±âÀü¿¬±¸¿ø
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
08.12 |
|
|
(ÁÖ)À¯¿µÁ¦¾à |
[°æ·Â] Á¦Á¦¿¬±¸ÆÀ ¸ðÁý
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
05.26 |
05.17 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
08.18 |
|
|
(ÁÖ)Çѱ¹ÀǾ࿬±¸¼Ò |
DM °æ·Â»ç¿ø ¸ðÁý
°æ±â ¼º³²½Ã Áß¿ø±¸ | Çз¹«°ü |
STAT/DM |
5³â¡è |
ä¿ë½Ã |
04.16 |
|
|
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ |
½Ã¹ÍÄÚ¸®¾Æ Trainer / QOL(Quality Oversight Leadership)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
02.07 |
|
|
(ÁÖ)ÄɾîÁ¨ |
¢ßÄɾîÁ¨ - ÆéŸÀ̵å ÇÕ¼º Àü¹®°¡ ¸ðÁý
°æ±â ±ºÆ÷½Ã | ´ëÇÐ(2~3³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
»ó½Ãä¿ë |
03.31 |
|
|
ÁöÀÌÇコÄɾîÄÚ¸®¾Æ |
GE Healthcare Scientist ¹ÙÀÌ¿ÀÀǾàÇ° ºÐ¼®¾÷¹«
ÀÎõ ¿¬¼ö±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
01.30 |
|